GGZ Delfland, PO Box 5016, 2600 GA Delft, The Netherlands.
Curr Treat Options Neurol. 2010 Sep;12(5):424-33. doi: 10.1007/s11940-010-0088-3. Epub 2010 Jul 10.
Irritability is a common neuropsychiatric feature of Huntington's disease (HD), with prevalences varying from 38% to 73%. Similar prevalences of irritability are reported in other neurodegenerative disorders and traumatic brain injury, especially when the frontal lobe is involved. Before therapeutic interventions are initiated, the clinician should analyze the severity and frequency of the irritable behavior. By examining irritability in a broader spectrum, a tailor-made treatment can be provided.In general, I recommend as a first step a selective serotonin reuptake inhibitor (SSRI), such as sertraline, or the mood stabilizer valproate; they both have a mild side effect profile. Next, if the result is insufficient, I advise a switch between these two medications. As an alternative, I recommend a switch to a low dose of an atypical antipsychotic, preferably twice daily. Buspirone may be another alternative. Both antipsychotics and buspirone are also used as an add-on. Other mood stabilizers and beta-adrenergic receptor antagonists should only be used when earlier treatments are ineffective. The use of acetylcholinesterase inhibitors for the treatment of irritability is discouraged, as results are unclear. Synthetic cannabinoids are an interesting new therapeutic option, though their "illicit" compound and side effect profile make them not a first-line option.It is important to identify possible comorbid psychiatric disorders, because irritability may be secondary to a psychiatric condition, and the choice of medication partly depends on the co-occurrence of a specific psychiatric disorder. For example, antipsychotic medication would be the treatment of choice in delusional HD patients with excessive irritability, instead of an SSRI or valproate.Besides psychiatric comorbidity, the choice of medication also depends on the general medical condition, the side effect profile, and drug-drug interactions with other medications in concomitant use. Patients with advanced disease are particularly likely to be using various other types of medications.In addition to pharmacotherapy, behavioral therapy or other psychotherapeutic interventions may be helpful to reduce levels of stress and should be considered.
易激惹是亨廷顿病(HD)的常见神经精神特征,患病率从 38%到 73%不等。在其他神经退行性疾病和创伤性脑损伤中,也有类似的易激惹患病率报道,尤其是当额叶受累时。在开始治疗干预之前,临床医生应分析易激惹行为的严重程度和频率。通过更广泛地检查易激惹,可以提供针对性的治疗。一般来说,我建议首先使用选择性 5-羟色胺再摄取抑制剂(SSRIs),如舍曲林,或心境稳定剂丙戊酸;它们都有轻度的副作用谱。其次,如果效果不理想,我建议在这两种药物之间进行转换。作为替代方案,我建议换用低剂量的非典型抗精神病药,最好每天两次。丁螺环酮也可能是另一种选择。抗精神病药和丁螺环酮也可作为附加药物。只有在早期治疗无效时,才应使用其他心境稳定剂和β肾上腺素能受体拮抗剂。不鼓励使用乙酰胆碱酯酶抑制剂治疗易激惹,因为结果尚不清楚。合成大麻素是一种有趣的新治疗选择,尽管它们的“非法”化合物和副作用谱使它们不是一线选择。识别可能存在的共患精神疾病很重要,因为易激惹可能继发于精神疾病,药物选择部分取决于特定精神疾病的共发情况。例如,对于易激惹的妄想型 HD 患者,抗精神病药物将是首选治疗药物,而不是 SSRIs 或丙戊酸。除了精神共病,药物选择还取决于一般的身体状况、副作用谱以及与同时使用的其他药物的药物相互作用。晚期疾病患者尤其可能正在使用各种其他类型的药物。除了药物治疗外,行为治疗或其他心理治疗干预可能有助于降低压力水平,应予以考虑。